STRM.BIO, a US-based pre-clinical, VC-backed biotechnology company, announced on Wednesday that it has named Dawn Bell, PharmD as its new director.

Bell has served in leadership roles in global drug development, medical affairs, and portfolio strategy. She has served as VP, Clinical Development and Medical Affairs and member of the executive team for Novartis Canada, founding CEO of an Emory University spinout, GM of a commercial-stage rare disease company and early commercial leader at The Medicines Company.

Jonathan Thon, Ph.D., CEO and founder of STRM.BIO, said, 'We are excited to welcome Dawn to our board, as she brings exceptional strategic and operational experience and leadership to our organisation. Dawn has an impressive track record of creating value in the biopharmaceutical industry and fostering the growth of companies. She will be a tremendous resource for STRM.BIO as we continue to advance development of novel gene therapies.'